Influence of the severity and treatment of allergic rhinitis and asthma on SARS-CoV-2 infection / 中华预防医学杂志
Chinese Journal of Preventive Medicine
; (12): 1171-1175, 2023.
Article
en Zh
| WPRIM
| ID: wpr-1046174
Biblioteca responsable:
WPRO
ABSTRACT
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected 660 million people and resulted in 6.7 million deaths. At present, a variety of risk factors related to the severity of COVID-19 have been identified, but whether allergic rhinitis and asthma will affect SARS-CoV-2 infection remains controversial. In general, there is no sufficient evidence to support that allergic rhinitis or asthma is a risk factor for increasing the rate of SARS-CoV-2 infection or aggravating the disease. Some studies even show that atopy may be a protective factor to alleviate SARS-CoV-2 infection, which is related to the decreased expression of angiotensin-converting enzyme 2, the receptor required for SARS-CoV-2 to enter cells, in atopic individuals. This paper reviews the influence of the severity and treatment of allergic rhinitis and asthma on SARS-CoV-2 infection, in order to provide some references for establishing strategies for prevention, risk stratification and treatment of COVID-19.
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Asma
/
Peptidil-Dipeptidasa A
/
Rinitis Alérgica
/
SARS-CoV-2
/
COVID-19
Límite:
Humans
Idioma:
Zh
Revista:
Chinese Journal of Preventive Medicine
Año:
2023
Tipo del documento:
Article